Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Julphar
Fuji
UBS
Farmers Insurance

Generated: September 17, 2019

DrugPatentWatch Database Preview

Details for Patent: 9,278,101

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,278,101 protect, and when does it expire?

Patent 9,278,101 protects OMIDRIA and is included in one NDA.

Protection for OMIDRIA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has twenty-eight patent family members in fourteen countries.

Summary for Patent: 9,278,101
Title:Ophthalmologic irrigation solutions and method
Abstract: Solutions for perioperative intraocular application by continuous irrigation during ophthalmologic procedures are provided. These solutions include multiple agents that act to inhibit inflammation, inhibit pain, effect mydriasis (dilation of the pupil), and/or decrease intraocular pressure, wherein the multiple agents are selected to target multiple molecular targets to achieve multiple differing physiologic functions, and are included in dilute concentrations in a balanced salt solution carrier.
Inventor(s): Demopulos; Gregory A. (Mercer Island, WA), Palmer; Pamela Pierce (San Francisco, CA), Herz; Jeffrey M. (Mill Creek, WA)
Assignee: Omeros Corporation (Seattle, WA)
Application Number:14/186,146
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,278,101
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation;

Drugs Protected by US Patent 9,278,101

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Omeros OMIDRIA ketorolac tromethamine; phenylephrine hydrochloride SOLUTION;IRRIGATION 205388-001 May 30, 2014 AT RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Subscribe to access the full database, or try a Free Trial

International Family Members for US Patent 9,278,101

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2003261304 ➤ Sign Up
Australia 2009248461 ➤ Sign Up
Australia 2013202330 ➤ Sign Up
Australia 2016201834 ➤ Sign Up
Australia 2018200887 ➤ Sign Up
Canada 2493581 ➤ Sign Up
Canada 2866848 ➤ Sign Up
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
QuintilesIMS
Express Scripts
Fuji
Baxter
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.